Search results for: Oncology
Filter search results
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…payers around the world. Indeed, experts agree combination therapies will become increasingly important in oncology. A new Editorial, Not Cost-effective at Zero Price, in Expert Review of Pharmacoeconomics and Outcomes…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
…therapies represent a new era in how oncology patients are diagnosed and treated, by targeting a genomic alteration within all solid tumours regardless of where the primary tumour is in…
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
…oncology treatments was put in place in 2011, with the establishment of a £200m dedicated fund for new oncology medicines not recommended by NICE. The rationale for this was twofold:…
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
In order to improve the diagnostic landscape in oncology and address a known gap or limitation in current diagnostic tools, a Target Product Profile (TPP) could be used as a…
OHE at HTAi 2017: Meet the Team
13 June 2017
…ten potential elements of value, four familiar ones and six new. These are highlighted in a recent OHE-AIM report. Presentation: Extrapolation From Progression Free Survival To Overall Survival In Oncology…
OHE at HTAi Rome
12 July 2017
…Overall Survival (OS) in Oncology. This presentation looked at the methods used to extrapolate PFS to OS in the field of oncology, as well as at the key limitations, weaknesses…
Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?
27 July 2023
…1995–2014 (ICBP SURVMARK-2): a population-based study” The Lancet Oncology Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study – The Lancet Oncology…
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…will be curtailed, particularly if a drug is nearing price negotiation time. This could limit new indication launches, an important (and efficient) source of new treatment opportunities, particularly in oncology…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
…Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe. OHE’s Adrian Towse participated in a two-day workshop convened…